Drug to Target and target profiling
We have developed a number of complementary technologies that allow biopharma companies to fully understand the complete target profile of the compounds under development previous to starting the actual systems biology work.
Anaxomics uses the following chemical modelling approaches:
Typically, the complete target profile of a new compound can be ellucidated by chemical and biological modelling , and refined and validated by using a combination of experimental in vitro and in vivo technologies. Here, new targets of drug D can be hypothezised by Binding Site Similarity techniques
Besides the chemical modelling, Anaxomics and its partners conduct advanced in vitro and in vivo experiments to refine the identity of the individual drug targets.
Anaxomics conducts the work through a series of qualified providers:
- -Yeast Three Hybrids systems through Dualsystems
- -High Throughput Library Screening
- - Mytochondrial function screening
Typically Anaxomics conducts the project management of these expert providers and technologies, offering an expert and consistent target profile for the drugs or compounds studied.